CoViD-19: Inflammation and Molecular Imaging

Session

Diagnostics - Imaging Agents

21 May 2021, 15:00

Remote

Conveners

Diagnostics - Imaging Agents: Present Status

• Marco Capogni (ENEA)
• Arturo Chiti (Humanitas University – Milan – Italy)

Diagnostics - Imaging Agents: Molecular Imaging

• José María Benlloch Baviera (I3M-CSIC)
• Luca Filippi (Santa Maria Goretti Hospital, Latina )

61. Understanding the radiation risks associated with molecular imaging

Michael K. O'Connor (Mayo Clinic, Section of Nuclear Medicine, Rochester)

21/05/2021, 15:00

Talk

62. Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in patients with COVID-19

Arturo Chiti (Humanitas University – Milan – Italy)

21/05/2021, 15:20

Talk

18. What molecular imaging of cancer patients can teach us about COVID-19

Silvana Del Vecchio (Nuclear Medicine, Department of Advanced Biomedical Sciences, University Federico II)

21/05/2021, 15:40

Talk

20. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?

Prof. E. Guedj (Nuclear Medicine, Univ. Marseille)

21/05/2021, 16:15

Talk

29. The role for dynamic imaging

Irène Buvat (Curie Institute – Orsay)

21/05/2021, 16:35

Talk

89. The case for the Total Body PET imaging of CD8+ T Cells for researching COVID-19

Terry Jones (University of California Davis)

21/05/2021, 17:05

Talk

66. Imaging Immune phenomena

Martin Pomper (Johns Hopkins – Baltimore)

21/05/2021, 17:25

Talk

30. Potential Role of Conventional and Total Body PET Imaging in Assessing Systemic Complications of COVID Infection

Abass Alavi (Penn Medicine, University of Pennsylvania)

21/05/2021, 17:45

Talk